Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B).
Tsubata Y, Watanabe K, Saito R, Nakamura A, Yoshioka H, Morita M, Honda R, Kanaji N, Ohizumi S, Jingu D, Nakagawa T, Nakazawa K, Mouri A, Takeuchi S, Furuya N, Akazawa Y, Miura K, Ichihara E, Maemondo M, Morita S, Kobayashi K, Isobe T.
Tsubata Y, et al. Among authors: nakazawa k.
Int J Clin Oncol. 2022 Jan;27(1):112-120. doi: 10.1007/s10147-021-02043-2. Epub 2021 Oct 13.
Int J Clin Oncol. 2022.
PMID: 34643820
Free PMC article.
Clinical Trial.